Srivastava KD, Dunkin D, Liu C, Yang N, Miller RL, Sampson HA, et al
This study, lasting 68 weeks, assesses the efficacy and safety of subcutaneous CagriSema (a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) in comparison to its individual components: cagrilintide 2.4 mg, semaglutide 2.4 mg, and a placebo, all administered weekly
Chemical promotion of HGF functions (enhanced receptor binding-affinity and nitration resistance) opens a new perspective from which the therapeutic effectiveness of HGF drugs and their effective tissue-specific delivery could be improved
Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin
For intranasal testing protocols (Semax, Selank), the vehicle can be sterile physiological saline (0.9% NaCl)
Wen M, Chen Q, Chen W, Yang J, Zhou X, Zhang C, et al